SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Natera Shares Are Trading Higher After Canaccord Genuity Raised Its Price Target on the Stock From $165 to $180.
The S&P 500's 10 Worst Performing Stocks in 2023 Fell Again in 2024
Natera Analyst Ratings
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Best and Worst Performing S&P 500 Stocks in a Rosy Year for Index
Santa Claus Came Without Rallying the Troops | Live Stock
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
How Is The Market Feeling About United Therapeutics?
Peering Into Moderna's Recent Short Interest
Top U.S. Health Care Mid-cap Stocks and Their Quant Ratings
Why Did Pfizer's Exit From the Gene Therapy Program Hit Sangamo Hard?
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Weekly Buzz: So far, Santa is Letting us Down
Bristol-Myers Squibb's Opdivo Qvantig Gets US FDA Approval
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock